EN DE

Nuchev Limited (NUC) Fair Value & Analysis

Consumer Defensive · AU · Market cap A$13.3M

NL Nuchev Limited NUC · AU
PriceA$0.0850
Fair ValueA$0.0255
Upside-70.0%
Quality48/100
Watch Nuchev Limited for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Loss-making · -18.9% net margin
Low debt · negative free cash flow
Mixed vs. peers (4/10)
Narrow moat 10/100
Evidence: Low Range A$0.0181 – A$0.0325 Share as image

Fair value as of: Jul 16, 2026

From 3 valuation models · updated 24 days ago

Share price +6.3% over the past month.

Below-average quality, and screening another 70% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (A$0.0325). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

A$0.8300 A$0.0700 Fair Value A$0.0255 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.

How to read this chart

60‑month range A$0.0700 – A$0.8300 · fair‑value band A$0.0181 – A$0.0325 · the A$0.0850 price screens above the A$0.0255 fair value. Dashed = 300-day average. As of Jul 16, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Nuchev Limited (NUC) currently trades at A$0.0850, while our model-based Fair Value estimate is A$0.0255, implying the stock looks roughly 70.0% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Nuchev Limited generated revenue of A$24.3M at a net margin of -18.9%. Revenue grew 12.0% year over year. It earns a return on equity of -38.0%. The balance sheet holds a net cash position of A$3.2M. Fundamentals as of Jul 16, 2026

Our scenario range runs from A$0.0181 (bear case) to A$0.0325 (bull case); at A$0.0850, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at -70%, NUC screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Gordon GGM A$0.0100 A$0.0100 A$0.0100 70
DDM Multi-Stage A$0.0100 A$0.0100 A$0.0100 61
NCAV (Graham) A$0.0400 A$0.0500 A$0.0700 50
All 3 models by family
Dividend Discount
Gordon GGM A$0.0100 A$0.0100 A$0.0100 70
DDM Multi-Stage A$0.0100 A$0.0100 A$0.0100 61
Asset-Based
NCAV (Graham) A$0.0400 A$0.0500 A$0.0700 50

Widest divergence: Asset-Based (A$0.0500) versus Dividend Discount (A$0.0100). Highest evidence: Gordon GGM (70).

Notify me when NUC reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) A$24.3M
Revenue growth (YoY) +12.0%
Net margin -18.9%
Return on equity -38.0%
Free cash flow −A$3.9M FY2025
Operating margin -19.5%
More key figures
EPS (TTM) A$-0.0300
Net cash A$3.2M FY2025

Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 48/100

Of which business quality 49 · Market factors (momentum, volatility) 13

Profitability 40
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Nuchev Limited, a health and nutrition solutions company, produces, markets, and sells nutritional and vitamin and dietary supplement products in Australia and China. The company offers goat and bovine milk-based formula and nutritional products under the Oli6 brand.

Full company description

Nuchev Limited, a health and nutrition solutions company, produces, markets, and sells nutritional and vitamin and dietary supplement products in Australia and China. The company offers goat and bovine milk-based formula and nutritional products under the Oli6 brand. It sells its products through pharmacy, grocery, and other retail channels, as well as e-commerce channels. The company was incorporated in 2013 and is headquartered in Melbourne, Australia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Nuchev Limited reported revenue of A$22.9M in FY2025 versus A$10.9M in FY2021, a compound +20.4%/yr. Reported net income was −A$3.8M in FY2025.

Growth Quality 23/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
A$22.9M
Latest YoY
+102.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+33.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.2%
Avg. growth/yr (8Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+31.6%
Revenue +20.4%/yr
FY21 A$10.9M
FY22 A$9.7M
FY23 A$8.8M
FY24 A$11.3M
FY25 A$22.9M
Net income
FY21 −A$13.3M
FY22 −A$11.1M
FY23 −A$8.8M
FY24 −A$7.3M
FY25 −A$3.8M

NUC screens 70% overvalued. Compare with Nestlé India Limited →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Nuchev Limited Fair Value". https://www.fairvalue-calculator.com/stock/NUC

Peer Group

Packaged Foods · 649 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 48 · Below median
Fair Value upside −70% · Bottom 25%
Return on assets -18% · Bottom 25%
Net margin (TTM) -19% · Bottom 25%
Operating margin (TTM) -19% · Bottom 25%
Revenue growth 12% · Above median

Valuation Multiples vs Packaged Foods median · lower = cheaper

P/B 0.84× · Cheaper than median
P/S (TTM) 0.39× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 28
FUTURE 60 · sector 20
PAST 0 · sector 27
HEALTH 100 · sector 96
DIVIDEND 0 · sector 47

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).

Stock Price Fair Value vs Fair Value
Nestlé India Limited NESTLEIND ₹1,427 ₹362.37 -75%
Britannia Industries Limited BRITANNIA ₹5,413 ₹1,870 -65%
Tata Consumer Products Limited TATACONSUM ₹1,089 ₹327.27 -70%
PT Indofood CBP Sukses Makmur Tbk ICBP 6,650 IDR 15,757 IDR +137%
Samyang Foods Co 003230 1,139,000 KRW 1,010,543 KRW -11%
Patanjali Foods Limited PATANJALI ₹413.80 ₹157.04 -62%
Vietnam Dairy Products Joint Stock Company VNM 58,500 VND 68,259 VND +17%
PT Mayora Indah Tbk, MYOR 1,750 IDR 2,699 IDR +54%
PT Cisarua Mountain Dairy Tbk CMRY 4,490 IDR 4,355 IDR -3%
Nongshim Co 004370 348,500 KRW 530,619 KRW +52%

Compare Nuchev Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Nuchev Limited (NUC) overvalued or undervalued?
As of Jul 16, 2026, our model estimates a fair value of A$0.0255 versus a price of A$0.0850, about −70% (overvalued).
What is the fair value of NUC?
Our model-based fair value for Nuchev Limited is A$0.0255 (as of Jul 16, 2026), built from audited fundamentals. The current price is A$0.0850.
What is the quality score of NUC?
Nuchev Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Nuchev Limited (NUC)?
Nuchev Limited reported trailing-twelve-month revenue of about A$24.3M (latest available figure, as of Jul 16, 2026).
What is the net profit margin of NUC?
The net profit margin of Nuchev Limited is about -18.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Nuchev Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.